Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study
Patients with MM are at very high risk of SREs. When receiving BTAs with a preventive intent, only a minority (<10%) experienced an SRE. These data suggest that preventive BTA use, effectively reduces the risk of SREs in real-life clinical practice.
Authors
- Valentina Ianakieva
- Veselina Goranova‐Marinova (ORCID: https://orcid.org/0000-0002-7811-162X)
- Georgi Mihaylov (ORCID: https://orcid.org/0000-0002-8435-2825)
- Zornitsa Katrandzhieva
- Kristiyan Karaasenov
Institutions
- Amgen (United States) (US)
- University Hospital Dr. Georgi Stranski (BG)
- University Specialized Hospital for Active Treatment of Endocrinology (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Bulgarian Food Safety Agency (BG)
Publication Details
- Journal
- Hematology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1080/16078454.2026.2631213
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00